Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

The global lung cancer therapeutics market is on a robust growth trajectory, poised to witness a significant transformation over the next decade. According to recent market projections, the industry ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

YAP, a protein known to help cancer cells survive treatment, behaves very differently in cell culture models depending on how they are grown in the lab, highlighting the importance of mimicking tumour ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...